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Abstract
Background: Early growth of HIV-exposed, uninfected (HEU) children is poorer than that of their HIV-unexposed,
uninfected (HUU) counterparts but there is little longitudinal or longer term information about the growth effects
of early HIV exposure.
Methods: We performed a longitudinal analysis to compare growth of HEU and HUU infants and children using
data from two cohort studies in Lusaka, Zambia. Initially 207 HUU and 200 HEU infants from the Breastfeeding and
Postpartum Health (BFPH) study and 580 HUU and 165 HEU from the Chilenje Infant Growth, Nutrition and
Infection Study (CIGNIS) had anthropometric measurements taken during infancy and again when school-aged, at
which time 66 BFPH children and 326 CIGNIS children were available. We analysed the data from the two cohorts
separately using linear mixed models. Linear regression models were used as a secondary analysis at the later time
points, adjusting for breastfeeding duration. We explored when the main group differences in growth emerged in
order to estimate the largest ‘effect periods’.
Results: After adjusting for socioeconomic status and maternal education, HEU children had lower weight-for-age,
length-for-age and BMI-for-age Z-scores during early growth and these differences still existed when children were
school-aged. Exposure group differences changed most between 1 and 6 weeks and between 18 months and ~7.5 years.
Conclusions: HEU children have poorer early growth than HUU children which persists into later growth. Interventions to
improve growth of HEU children need to target pregnant women and infants.
Keywords: HIV-exposed uninfected, Child, Growth, Longitudinal
Background
Africa contains the majority of the world’s Human Im-
munodeficiency Virus (HIV)-infected people. UNAIDS
estimated that there were 27,000 deaths from Acquired
Immunodeficiency Syndrome (AIDS) in Zambia, and
over 1 million people living with HIV in 2013 [1]. There
has been a big drive to eliminate mother-to-child HIV
transmission and to do so by 2015 was one of the targets
of the 2011 United Nations Zambia Country Progress
Report [2]. As a result of public health interventions,
rates of mother-to-child HIV transmission have been
falling and more children are being born HIV-exposed
yet uninfected (HEU).
There has been some research into the health and
growth of HEU children from different parts of the
world [3, 4]. However, most data from Africa, the centre
of the HIV epidemic, is restricted to infancy and early
childhood [5–10] or lacks appropriate non-HIV-exposed
controls [11]. In spite of these data limitations, as well as
the varying exposure to antiretroviral drugs in these
studies, there is evidence of both linear and ponderal
growth faltering in HEU children. The aim of this
analysis was to determine whether the early and later
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growth, measured as weight-for-age, height-for-age and
body mass index (BMI)-for-age Z-scores, of HIV-
unexposed-uninfected (HUU) and HEU children differ.
The analysis also aimed to estimate the ‘effect periods’,
i.e. those periods when the difference between the two
exposure groups changed the most, in order to attempt
to determine whether effects occur solely in utero, in
infancy, or the effect which occurs in utero or in
infancy then worsens or improves as the child grows.
We controlled for socioeconomic factors in order to
estimate whether any differences were more likely
biological or social.
Methods
Participants
The data used for the analysis came from two cohorts of
children from Lusaka, Zambia. The Breastfeeding and
Postpartum Health Study (BFPH) [6, 12] was conducted
from June 2001 to July 2003. The HIV status of all
mothers was known through antenatal antibody testing
at the local government clinic. BFPH infants were not
HIV-tested in the original study since they were followed
to only 16 weeks of age at a time when PCR testing was
unavailable at the site; we did not have ethical approval
to test for HIV at later time points so have HIV status
information only for those who happened to be tested at
local clinics, likely because they were ill. At the time of
the study the only antiretroviral regimen available for
prevention of mother-to-child transmission (PMTCT) in
the area was perinatal nevirapine to both mother and in-
fant. The median duration of exclusive breast feeding
was 6 weeks for HIV-infected women and 9 weeks for
HIV-uninfected women [13] and the median duration of
any breast feeding was 17 months and 18 months for
these groups, respectively, for children who remained
HEU (unpublished). In a previous analysis, early growth
of infants from 218 HIV-infected and 211 HIV-
uninfected mothers was compared at birth, 6 and 16
weeks [6]. HIV-exposed infants had lower weight-for-age
and length-for-age Z-scores at each time of measure-
ment, controlling for gestational age, compared to HUU
infants. At a median age of 2.7 years a subset of 205
children (107 HEU, 98 HUU) were followed up and
measurements of weights and lengths were taken [6].
A further follow-up of 66 children, median age 11.6
years, took place (33 HUU, 33 HEU) in May 2014
[14]. Further details of follow-up study methods have
been described previously.
The Chilenje Infant Growth, Nutrition and Infection
Study (CIGNIS) was a double-blind randomised con-
trolled trial conducted from October 2005 to July 2009
[15]. 811 infants were enrolled aged 6 months and ran-
domised to one of two complementary foods, differing
in micronutrient content, for 12 months. Maternal and
child HIV status was assessed by antibody testing in the
local clinic; women were mostly tested during antenatal
care and children were tested at 18 months. Anthropo-
metric measurements were taken at 6, 9, 12, 15 and 18
months. At the time of the study perinatal nevirapine
was the local regimen for PMTCT. Antiretroviral ther-
apy (ART) was available only for adults with CD4 count
< 200 cells/μL until towards the end of the study when
the cut-off was changed to < 350 cells/μL; few of the
CIGNIS children’s mothers were on any ART. HIV-
infected mothers were less likely to initiate breast feed-
ing and stopped earlier compared to uninfected mothers
[16]. A random effects regression analysis (controlling
for treatment group, visit, socioeconomic status, mater-
nal education, current breast feeding and sex), which in-
cluded only children who had been followed up for the
complete 18 months, found that HEU children had
lower mean length-for-age and weight-for-age Z-scores
than HUU children [17]. For the present analyses, HIV-
infected children and children whose mother’s HIV
status was unknown were excluded. Hence, weights and
heights for 745 children (580 HUU, 165 HEU) were
included in analyses; birthweights were also available for
737 children. A subset of the children (247 HUU, 79
HEU) was followed up when the children were at a
median age of 7.5 years, in May 2014 [14].
At the later time points in both studies only a subset
of children originally recruited were followed-up due to
a lack of substantial funding. Mothers previously HIV--
negative were not retested for HIV since we were inter-
ested in children’s exposure in utero and in infancy.
Anthropometry
Anthropometric measurements for both studies and all
time points were conducted or supervised by the same
research nurse. Standard methods were used [18] and
measurements made in duplicate (BFPH) or triplicate
(CIGNIS and follow-up). Training and monitoring of
staff was by assessment of the technical error of
measurement [19].
Statistical analysis
All analyses were carried out in Stata v13. Separately in
each study, a linear mixed model was used to estimate
the differences in anthropometric Z-scores (based on the
WHO 2006/2007 growth standards) [20] between HUU
and HEU children. In the BFPH cohort weight-for-age
Z-scores could not be compared at the later visit since
WHO provides weight-for-age Z-score references for
children only up to the age of 10 and all but one child
were 10 years or over.
We assumed missing data were missing at random
(MAR), which essentially means that drop out at a given
follow-up time is independent of outcome at that time,
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after adjustment for the previous measures of outcome
(and other covariates, if adjusted for) [21]. The outcomes
were weight-for-age, length/height-for-age and BMI-for-
age Z-scores. In order to give an estimate of the difference
at each time point, these models included time as a cat-
egorical variable with an interaction between time and ex-
posure group. Within-child residuals were modelled with
an unstructured covariance matrix. These models account
for correlations between repeated measurements of the
same child over time and also include all available data,
i.e. if a child had missing data at one of the visits they were
not discarded from the analysis and the available data
from previous visits was included resulting in more pre-
cise estimates in comparison to complete case analysis.
Maternal education and socioeconomic status are
known to be associated with poor growth of children in
this community [5]; hence both cohorts were adjusted
according to information collected as part of each study.
The Z-scores already control for age and sex so these
factors were not further controlled for. The models esti-
mating differences in the BFPH cohort were adjusted for
maternal education (primary, secondary, tertiary) and
housing density (low, middle, high) as housing density
was the closest available indication of socioeconomic
status, both measured at recruitment. The CIGNIS
models were adjusted for maternal education (primary
or less, secondary, college/university) and socioeconomic
group, based on an asset index score (low, middle, high),
both measured at recruitment. We did not adjust for
treatment group from the CIGNIS trial when children
were 6–18 months since it had limited effect even in in-
fancy and none by the time children were school-aged.
Linear regression models, using only available data at
each time point, were used as a secondary analysis for
the later time points (~2.7, ~7.5 and ~11.6 years) also
adjusting for breast feeding duration in order to estimate
direct effects of HIV exposure not mediated via breast
feeding. For BFPH this was categorised by <18 months,
18+ months since this was the median for all children.
For CIGNIS, breast feeding duration was categorised by
<12 months, 12+ months as a compromise since earlier
papers used 6 months as a cut-off for HEU children and
18 months for HUU children. Note that median
duration of breast feeding differed between the two
cohorts because infants were born when different HIV
and infant feeding recommendations were in place.
The linear mixed models were also used to estimate
‘effect periods’. The changes in differences of Z-scores
between HEU and HUU children from each time point
to its preceding time point were calculated. For instance,
the difference in weight-for-age Z-scores at birth was
subtracted from the difference in weight-for-age Z-
scores at 6 months to estimate by how much the differ-
ence between HUU and HEU infants changed from birth
to 6 months. P-values from Wald tests and 95% confi-
dence intervals were calculated.
Results
Table 1 provides descriptive data for both cohorts and
Table 2 shows the number of children participating at
each time point in the two studies. With the exception
of week 1 length in the BFPH cohort, at each visit point
estimates for anthropometry suggested that HEU chil-
dren in both cohorts were shorter and lighter than HUU
children (Table 2). For the BFPH cohort, after adjusting
for maternal education and housing density, there was
evidence at the 5% level that weight-for-age Z-scores
were lower in HEU children compared with HUU chil-
dren (Fig. 1 and Table 3) at all time points. There was
evidence of borderline differences in length/height-for-
age Z-scores at 6 weeks and at all subsequent time
points. Up to 16 weeks there was strong evidence of dif-
ferences in BMI-for-age Z-scores with HEU children es-
timated to have ~0.4 lower Z-scores than HUU children.
There was no statistically significant evidence of differ-
ences at the later time points. A secondary analysis
adjusting for breast-feeding duration at the later time
Table 1 Baseline demographic summary statistics
HIV-
unexposed
HIV-exposed-
uninfected
Breast Feeding and Postpartum Health (BFPH) study
N 207 (50.9) 200 (49.1)
Sex (N % female) - 107 (51.7) 106 (53.0)
Housing density (N %) High 49 (22.6) 49 (23.2)
Middle 139 (64.1) 140 (66.4)
Low 29 (13.4) 22 (10.4)
Maternal Education
(N %)
Primary 34 (15.7) 35 (16.6)
Secondary 126 (58.1) 118 (55.9)
Tertiary 57 (26.3) 58 (27.5)
Breast-fed (N %) <18 months 32 (31.1) 52 (54.2)
18+ months 71 (68.9) 44 (45.8)
Chilenje Infant Growth, Nutrition and Infection Study (CIGNIS)
N 580 (77.9) 165 (22.1)
Sex (N % female) - 302 (52.1) 91 (55.2)
Socioeconomic groupa
(N %)
Low 179 (30.9) 67 (40.6)
Middle 227 (39.1) 57 (34.6)
High 174 (30.0) 41 (24.9)
Maternal Education
(N %)
Primary or less 174 (30.0) 66 (40.0)
Secondary 225 (38.8) 60 (36.4)
College/university 181 (31.2) 39 (23.6)
Breast-fed (N %) <12 months 150 (25.9) 138 (83.6)
12+ months 430 (74.1) 27 (16.4)
aBased on an asset index score
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points gave more conservative estimates for weight-for-
age and height-for-age differences suggesting that some
of the differences between the two groups are due to dif-
ferences in breast-feeding duration (Additional file 1:
Table S1). There was borderline difference in height-for-
age at ~2.7 years but no evidence of other differences
between the two groups of BFPH children.
For the CIGNIS children, in the adjusted analyses
there was statistically significant evidence of differences
in weight-for-age and length-for-age between the two
groups of children at most time points from 6 months
to 18 months but of differences in BMI-for-age only at 6
and 15 months and ~7.5 years (Fig. 1 and Table 3). By
~7.5 years HEU children had a 0.15 (95% CI [−0.09,
0.39] p = 0.22) lower weight-for-age Z-score compared
with HUU children and an estimated 0.31 (95% CI [0.03,
0.59] p = 0.03) lower BMI-for-age. Height-for-age Z-
scores did not differ between groups. When adjusting
for breast-feeding duration at ~7.5 years in the second-
ary analysis, the point estimates of weight for age re-
duced very slightly (compared to those not adjusting for
breast-feeding), while estimated differences in length-
for-age and BMI-for-age increased somewhat. There was
evidence of a difference (p = 0.02) in BMI-for-age
Z-scores but not of differences in weight-for-age or
height-for-age Z-scores, although confidence intervals
were wide (Additional file 1: Table S1).
Effect periods
Table 4 shows the estimated incremental changes over
time in the exposure group differences in outcomes. In
BFPH there was borderline statistically significant
evidence of an increasing difference in weight-for-
age (p = 0.06) and length-for-age (p = 0.03) Z-scores
between 1 and 6 weeks suggesting that this could be
a period where maternal HIV exposure has a large
effect on growth. Differences in weight-for-age and
length-for-age Z-scores then remained fairly constant
between 6 and 16 weeks. Differences in BMI-for-age
Z-scores remained fairly constant between 1 and 16
weeks but then there was evidence of a significant
change (p = 0.03) between 16 weeks and ~2.7 years.
Length/height-for-age exhibited a contrasting pattern
between 16 weeks and ~2.7 years with the difference
in length/height-for-age estimated to increase; how-
ever there was no evidence against the null of these
changes in differences being zero. By ~11.6 years the
change in group difference in BMI-for-age grew
closer to zero and also decreased for length-for-age.
For CIGNIS children, differences in weight-for-age Z-
scores remained fairly constant from birth up to ~7.5
years. Differences in length-for-age and BMI-for-age Z-
scores remained fairly constant between 6 and 18 months.
Between 18 months and ~7.5 years there was evidence for
a decreased difference in length-for-age (p < 0.01) and an
increased difference in BMI-for-age (p = 0.07).
Discussion
The results indicate that the differences in growth be-
tween HEU and HUU occur mainly before birth or in
early life with limited either worsening or catch-up in
later childhood. Because both cohorts were from the
same community and were studied by the same research
Table 2 Numbers available, mean (SD) weights and lengths/
heights for available dataa by maternal HIV exposure
Breast Feeding and Postpartum Health (BFPH) study
Age (weeks/median years) Weight (kg) -
N, mean (SD)
Length/height
(cm) - N, mean (SD)
HUU HEU HUU HEU
1 week 207 200 174 171
3.0 (0.4) 2.9 (0.5) 49.4 (2.6) 49.6 (2.6)
6 weeks 178 173 178 174
5.1 (0.6) 4.8 (0.7) 55.0 (2.8) 54.4 (2.9)
16 weeks 175 168 174 169
6.8 (0.8) 6.5 (1.0) 61.9 (2.6) 61.2 (3.4)
~2.7 years 107 98 107 98
13.3 (2.1) 12.8 (2.4) 92.1 (8.3) 89.2 (7.9)
~11.6 years 33 33 33 33
38.5 (10.1) 37.2 (8.9) 145.3 (7.9) 143.2 (8.7)
Chilenje Infant Growth, Nutrition and Infection Study (CIGNIS)
Age (months/median years) Weight (kg) -
N, mean (SD)
Length/height
(cm) - N, mean (SD)
HUU HEU HUU HEU
Birthb 574 163 - -
3.1 (0.5) 3.0 (0.5)
6 months 580 165 580 165
7.4 (1.1) 7.1 (1.1) 65.0 (2.5) 64.3 (2.4)
9 months 506 152 506 152
8.3 (1.2) 8.0 (1.2) 69.4 (2.6) 68.7 (2.8)
12 months 470 152 469 151
9.0 (1.3) 8.7 (1.4) 73.0 (2.8) 72.3 (2.8)
15 months 446 144 445 142
9.6 (1.4) 9.2 (1.4) 76.1 (2.9) 75.1 (3.2)
18 months 446 141 445 141
10.2 (1.5) 9.8 (1.5) 78.8 (3.2) 77.6 (3.4)
~7.5 years 247 79 247 79
23.8 (5.4) 22.5 (3.8) 122.4 (6.6) 122.0 (6.5)
Abbreviations: HEU HIV-exposed, uninfected, HUU HIV-unexposed, uninfected
aThe majority of loss to follow-ups were inability to trace at later follow-ups for
funding and other reasons. 21 infants died during the original BFPH study and
12 during the original CIGNIS study. We have no information about later
deaths. 18 infants in the CIGNIS study were HIV-positive and thus excluded
from the analysis
bBirth weights of CIGNIS children were taken from Road-to-Health cards
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team, it is worth considering their results together for a
fuller picture of child growth differences, keeping in
mind the large differences in breast-feeding practices of
HIV-infected mothers in the BFPH and CIGNIS studies.
In previous studies breast-feeding among HIV-exposed
children has been associated with less faltering in early
weight growth [22]. Although both HIV-infected and
uninfected BFPH women breast-fed both exclusively and
at all for similar lengths of time, the decreased point es-
timates of group differences when we controlled for
breast-feeding duration supports this previous work.
However, controlling for breast feeding in the CIGNIS
study in which there were large differences in breast-
feeding duration between HIV-infected and uninfected
women had the opposite effect of increasing the point
estimates of differences. Breast milk quality or quantity
as well as breast-feeding duration may differ by maternal
HIV status: in the BFPH study, the HIV-infected women
had higher prevalence of subclinical mastitis, a condition
which in dairy cows is associated with reduced milk pro-
duction [12]. Although we did not measure breast milk
production, reduced milk production by HIV-infected
mothers is a possible cause of the increased weight and
length growth faltering of their HEU infants between 1
and 6 weeks. Although we found similar early growth
differentials between HEU and HUU children for length
as for weight-for-age and BMI-for-age, other studies of
HIV-exposed infants but lacking HUU controls found
variable associations of infant feeding with length-for-
age including no effect of breast feeding [23], reduced
growth with formula feeding [22], and better length
growth velocity with formula feeding [10]. It is likely that
local socioeconomic conditions as well as trial designs
which included providing formula account for these
differences. In our study it is important to realise that
the comparison group also growth faltered in infancy
since Chilenje has a fairly high level of childhood
stunting [24].
Fig. 1 Estimated BFPH and CIGNIS adjusteda differences in mean Z-scores between exposure groups given by the linear mixed models. aAdjusted
for maternal education (primary, secondary, tertiary) and housing density (high, medium, low) for BFPH and for maternal education (primary or
less, secondary, tertiary) and socioeconomic group (low, middle, high) for CIGNIS
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Table 3 Differencea in mean Z-score by maternal HIV status [95% CI] as estimated by the linear mixed models
Breast Feeding and Postpartum Health (BFPH) study
Age (weeks/median years) Unadjusted Adjustedb
WAZ L/HAZ BAZ WAZ L/HAZ BAZ
1 week 0.28 0.
[09, 0.47]
P < 0.01
−0.07
[−0.34, 0.21]
P = 0.64
0.44
[0.17, 0.72]
P < 0.01
0.29
[0.10, 0.48]
P < 0.01
−0.06
[−0.33, 0.22]
P = 0.68
0.46
[0.19, 0.73]
P < 0.01
6 weeks 0.47
[0.25, 0.69]
P < 0.01
0.31
[0.01, 0.60]
P = 0.04
0.42
[0.15, 0.69]
P < 0.01
0.46
[0.25, 0.68]
P < 0.01
0.29
[0.00, 0.59]
P = 0.05
0.41
[0.14, 0.68]
P < 0.01
16 weeks 0.52
[0.28, 0.75]
P < 0.01
0.31
[0.02, 0.61]
P = 0.04
0.42
[0.16, 0.69]
P < 0.01
0.51
[0.27, 0.75]
P < 0.01
0.29
[0.00, 0.59]
P = 0.05
0.42
[0.15, 0.68]
P < 0.01
~2.7 years 0.38
[0.02, 0.73]
P = 0.04
0.76
[0.21, 1.32]
P = 0.01
−0.23
[−0.77, 0.31]
P = 0.41
0.36
[0.01, 0.71]
P = 0.04
0.74
[0.18, 1.29]
P < 0.01
−0.23
[−0.77, 0.31]
P = 0.41
~11.6 years - 0.32
[−0.10, 0.75]
P = 0.14
−0.11
[−0.62, 0.40]
P = 0.67
- 0.38
[−0.02, 0.77]
P = 0.06
−0.14
[−0.65, 0.37]
P = 0.59
Chilenje Infant Growth, Nutrition and Infection Study (CIGNIS)
Age (months/median years) Unadjusted Adjustedc
WAZ L/HAZ BAZ WAZ L/HAZ BAZ
Birth 0.19
[0.00, 0.38]
P = 0.06
- - 0.15
[−0.05, 0.34]
P = 0.14
- -
6 months 0.35
[0.14, 0.56]
P < 0.01
0.24
[0.06, 0.42]
P = 0.01
0.28
[0.07, 0.48]
P < 0.01
0.28
[0.07, 0.49]
P < 0.01
0.17
[0.00, 0.35]
P = 0.06
0.24
[0.03, 0.44]
P = 0.02
9 months 0.31
[0.10, 0.52]
P < 0.01
0.26
[0.07, 0.45]
P < 0.01
0.23
[0.02, 0.43]
P = 0.03
0.25
[0.04, 0.45]
P = 0.02
0.18
[0.00, 0.37]
P = 0.05
0.19
[−0.01, 0.39]
P = 0.07
12 months 0.32
[0.11, 0.53]
P < 0.01
0.29
[0.10, 0.48]
P < 0.01
0.20
[−0.01, 0.41]
P = 0.06
0.22
[0.01, 0.42]
P = 0.04
0.20
[0.02, 0.39]
P = 0.03
0.13
[−0.07, 0.33]
P = 0.21
15 months 0.36
[0.15, 0.57]
P < 0.01
0.31
[0.12, 0.51]
P < 0.01
0.23
[0.03, 0.42]
P = 0.02
0.24
[0.03, 0.44]
P = 0.02
0.20
[0.02, 0.39]
P = 0.03
0.15
[−0.04, 0.34]
P = 0.13
18 months 0.32
[0.11, 0.53]
P < 0.01
0.39
[0.19, 0.59]
P < 0.01
0.11
[−0.08, 0.30]
P = 0.27
0.20
[−0.01, 0.40]
P = 0.06
0.24
[0.06, 0.43]
P = 0.01
0.05
[−0.14, 0.25]
P = 0.58
~7.5 years 0.27
[0.02, 0.52]
P = 0.03
0.05
[−0.15, 0.25]
P = 0.63
0.41
[0.13, 0.70]
P < 0.01
0.15
[−0.09, 0.39]
P = 0.22
−0.03
[−0.23, 0.16]
P = 0.75
0.31
[0.03, 0.59]
P = 0.03
WAZ weight-for-age Z-score, L/HAZ length/height-for-age Z-score, BAZ BMI-for-age Z-score, HEU HIV-exposed uninfected, HUU HIV-unexposed, uninfected
Sample sizes: BFPH - 1 week: WAZ - 207 HUU, 200 HEU; L/HAZ – 174 HUU, 171 HEU; BAZ – 174 HUU, 171 HEU; 6 weeks: WAZ – 178 HUU, 173 HEU; L/HAZ – 178
HUU, 174 HEU; BAZ – 178 HUU, 173 HEU; 16 weeks: WAZ – 175 HUU, 168 HEU; BAZ – 174 HUU, 168 HEU; ~2.7 years: WAZ – 107 HUU, 98 HEU; L/HAZ – 107 HUU,
98 HEU; BAZ – 107 HUU, 98 HEU; ~11.6 years: WAZ – 33 HUU, 33 HEU; L/HAZ – 33 HUU, 33 HEU, BAZ – 33 HUU, 33 HEU CIGNIS - Birth: WAZ – 574 HUU, 163 HEU;
6 months: WAZ – 580 HUU, 165 HEU; L/HAZ – 580 HUU, 165 HEU; BAZ – 580 HUU, 165 HEU; 9 months: WAZ – 506 HUU, 152 HEU; L/HAZ – 506 HUU, 152 HEU;
BAZ – 506 HUU, 152 HEU; 12 months: WAZ - 470 HUU; 152 HEU; L/HAZ – 469 HUU; 151 HEU; BAZ – 469 HUU, 151 HEU; 15 months: WAZ – 446 HUU; 144 HEU;
L/HAZ - 445 HUU; 142 HEU; BAZ – 445 HUU; 142 HEU; 18 months: WAZ – 446 HUU, 144 HEU; L/HAZ – 445 HUU, 141 HEU; BAZ – 445 HUU, 141 HEU; ~7.5 years:
WAZ – 247 HUU; 79 HEU; L/HAZ – 247 HUU; 79 HEU; BAZ – 247 HUU, 79 HEU
aHUU mean Z-scores minus HEU mean Z-scores
bAdjusted for maternal education (primary, secondary, tertiary) and housing density (high, medium, low)
cAdjusted for maternal education (primary or less, secondary, tertiary) and socioeconomic group (low, middle, high)
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There are few published studies with which to com-
pare our data from the older children. Weight-for-age
differentials between HEU and HUU children showed
relatively little change after 18 months. This is related to
the opposing changes in BMI and height because of the
definition, weight/height2, of BMI. In CIGNIS, between
18 months and ~7.5 years length-for-age Z-scores for
the HEU children caught up with their unexposed peers
but BMI differential worsened. In the BFPH cohort there
was worsening length/height-for-age from 16 weeks to
~2.7 years and decreasing differential in BMI-for-age.
This is different from a European cohort in which both
weight and BMI appeared above the British growth
standard mean by the time HEU children were school-
aged [3]. It is possible that the timing of growth spurts
differs between HEU and HUU children but this would
require further research.
Previous reports of growth of the BFPH [6] and
CIGNIS [5] children focussed on early growth and in the
current paper we present an extension of this. Further-
more, growth was previously analysed in the CIGNIS
cohort only for those who had complete data up to 18
months and in BFPH results were estimated using
complete case analysis. Due to the nature of mixed
models we have included all available data in our
analysis, which leads to more precise estimates.
Both BFPH and CIGNIS cohorts were born at a time
when ART availability was limited so the only drug used
for PMTCT was perinatal nevirapine. It is possible that
ART during pregnancy could reduce the in utero and in-
fancy growth differentials. However, since there is evi-
dence that some ART drugs during pregnancy are
associated with in utero growth deficits [7], the growth
differentials between HEU and HUU children might ac-
tually increase. In a European cohort, the increased
availability of ART in the 1990s had little effect on the
growth of HEU children [3]. Further research with Afri-
can infants exposed to ART in utero is needed.
One limitation of the analysis was that there were no
intermediate time points between 16 weeks, ~2.7 years
and ~11.6 years and between 18 months and ~7.5 years
which might have enabled effect periods to be defined
more precisely. Another limitation of the study is the
fact that only subsets of the original populations were
followed-up at the later time points - these subsets, in
addition to being fairly small, tended to be of a higher
socioeconomic status (i.e. those owning a telephone) and
for this reason socio-economic status was taken into
consideration when making adjustments in the analyses.
Our estimates could be biased however, if it were the
case that those children whose outcomes were not avail-
able at the later time were systematically different, after
taking into account baseline variables and early childhood
outcome measures (the missing at random assumption).
In addition, there could be residual, unmeasured con-
founding. Finally, for ethical reasons we did not retest pre-
viously HIV-negative children and relied on symptoms to
determine if any were likely to be HIV-infected; there
Table 4 Changes with time in differencesa of anthropometric Z-scores between the HUU and HEU children and infants
Weight-for-age Length/height-for-age BMI-for-age
Breast Feeding and Postpartum Health (BFPH) study
6–1 week 0.17 [0.01, 0.35] P = 0.06 0.35 [0.04, 0.66] P = 0.03 −0.05 [−0.39, 0.29] P = 0.77
16–6 weeks 0.05 [−0.13, 0.22] P = 0.59 0.00 [−0.27, 0.27] P = 0.99 0.01 [−0.27, 0.29] P = 0.95
~2.7 years-16 weeks −0.15 [−0.51, 0.21] P = 0.41 0.44 [−0.13, 1.02] P = 0.13 −0.64 [−1.24, 0.05] P = 0.03
~11.6 - ~ 2.7 years - −0.36 [−0.95, 0.24] P = 0.24 0.09 [−0.64, 0.82] P = 0.81
Chilenje Infant Growth, Nutrition and Infection Study (CIGNIS)
6 months-birth 0.13 [−0.08, 0.35] P = 0.22 - -
9–6 months 0.03 [−0.12, 0.06] P = 0.50 0.01 [−0.08, 0.10] P = 0.78 0.05 [−0.17, 0.07] P = 0.39
12–9 months −0.03 [−0.12, 0.05] P = 0.43 0.02 [−0.07, 0.11] P = 0.65 −0.06 [−0.17, 0.06] P = 0.35
15–12 months 0.02 [−0.05, 0.10] P = 0.58 0.00 [−0.08, 0.08] P = 0.96 0.02 [−0.09, 0.13] P = 0.74
18–15 months 0.04 [−0.11, 0.03] P = 0.25 0.04 [−0.04, 0.12] P = 0.30 −0.09 [−0.20, 0.01] 0.08
~7.5 years-18 months −0.04 [−0.27, 0.18] P = 0.70 −0.28 [−0.46, −0.09] P < 0.01 0.25 [−0.02, 0.53] P = 0.07
WAZ weight-for-age Z-score, L/HAZ length/height-for-age Z-score, BAZ BMI-for-age Z-score, HEU HIV-exposed, uninfected, HUU HIV-unexposed, uninfected
Sample sizes: BFPH - 1 week: WAZ - 207 HUU, 200 HEU; L/HAZ – 174 HUU, 171 HEU; BAZ – 174 HUU, 171 HEU; 6 weeks: WAZ – 178 HUU, 173 HEU; L/HAZ – 178
HUU, 174 HEU; BAZ – 178 HUU, 173 HEU; 16 weeks: WAZ – 175 HUU, 168 HEU; BAZ – 174 HUU, 168 HEU; ~2.7 years: WAZ – 107 HUU, 98 HEU; L/HAZ – 107 HUU,
98 HEU; BAZ – 107 HUU, 98 HEU; ~11.6 years: WAZ – 33 HUU, 33 HEU; L/HAZ – 33 HUU, 33 HEU, BAZ – 33 HUU, 33 HEU CIGNIS - Birth: WAZ – 574 HUU, 163 HEU;
6 months: WAZ – 580 HUU, 165 HEU; L/HAZ – 580 HUU, 165 HEU; BAZ – 580 HUU, 165 HEU; 9 months: WAZ – 506 HUU, 152 HEU; L/HAZ – 506 HUU, 152 HEU;
BAZ – 506 HUU, 152 HEU; 12 months: WAZ - 470 HUU; 152 HEU; L/HAZ – 469 HUU; 151 HEU; BAZ – 469 HUU, 151 HEU; 15 months: WAZ – 446 HUU; 144 HEU;
L/HAZ - 445 HUU; 142 HEU; BAZ – 445 HUU; 142 HEU; 18 months: WAZ – 446 HUU, 144 HEU; L/HAZ – 445 HUU, 141 HEU; BAZ – 445 HUU, 141 HEU; ~7.5 years:
WAZ – 247 HUU; 79 HEU; L/HAZ – 247 HUU; 79 HEU; BAZ – 247 HUU, 79 HEU
aDifference between HUU minus HEU at the later time point minus difference at the earlier time point, i.e. positive values indicate increasing differences
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could thus have been some HIV-infected slow progressors
among the HEU group. However, in a cross-sectional
study of these children, a secondary analysis including
only children confirmed HIV-negative found very simi-
lar results to the whole cohort [14].
Conclusion
There is very limited literature on the growth of HEU
children and much of what exists compares their growth
to HIV-infected children [22, 25, 26] as opposed to using
a HUU comparison group. We have been able to
compare growth of HEU children with that of an HUU
comparison group from the same population and of
similar socioeconomic status. HEU children had lower
weight-for-age, length-for-age and BMI-for-age Z-scores
during early growth and these differences still existed
when children were school-aged. This suggests that in-
terventions to improve growth need to target pregnant
women and infants. Further work into exploring the ef-
fect periods, including among children whose mothers
had access to ART during pregnancy, would enable ac-
tion to be taken in order to prevent these differences
and ensure the good health of this growing population.
Obviously additional efforts to decrease the number of
women becoming HIV-infected are also required in
order to reduce infant HIV exposure.
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